India
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 1 252 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 240 (150–350) 19 (12–28)
Mortality (HIV+TB only) 38 (31–44) 3 (2.5–3.5)
Prevalence  (includes HIV+TB) 2 600 (1 800–3 700) 211 (143–294)
Incidence  (includes HIV+TB) 2 100 (2 000–2 300) 171 (162–184)
Incidence (HIV+TB only) 120 (100–140) 9.7 (8.3–11)
Case detection, all forms (%) 58 (54–61)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.9–2.6) 15 (11–19)
MDR-TB cases among notified pulmonary
TB cases
20 000 (17 000–24 000) 41 000 (30 000–52 000)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 621 762   102 660
Pulmonary, clinically diagnosed 292 926    
Extrapulmonary 226 557    
       
Total new and relapse 1 243 905    
Previously treated, excluding relapses 171 712    
Total cases notified 1 415 617    
Among 1 243 905 new and relapse cases:
64 726 (5%) cases aged under 15 years;
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB     248 341
Laboratory-confirmed RR-/MDR-TB cases     35 385
Patients started on MDR-TB treatment     20 763
TB/HIV 2013 Number (%)
TB patients with known HIV status 887 903 (63)
HIV-positive TB patients 44 027 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 41 827 (95)
HIV-positive TB patients on antiretroviral therapy (ART) 38 754 (88)
HIV-positive people screened for TB 1 063 644  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 88
Previously treated cases, excluding relapse, registered in 2012 74
HIV-positive TB cases, all types, registered in 2012 77
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 54
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 252
% Funded domestically 66%
% Funded internationally 34%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-21 Data: www.who.int/tb/data